Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ediFCrsecrzZfHyVOdNX

  ADVERTISEMENT  
December 21, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
 
  • Robotic surgery limits blood loss in patients with bladder cancer
    Compared with open radical cystectomy, robotic-assisted laparoscopy for invasive bladder cancer led to 50% less blood loss, reduced hospital stays and a 20% lower transfusion rate, according to a randomized study published in the Journal of Urology. The study found no significant difference in cancer outcomes. "Our study validates the concept of randomizing patients with bladder cancer undergoing radical cystectomy to an open or robotic approach," the researchers said. MedPage Today (free registration) (12/20) LinkedInFacebookTwitterEmail this Story
 
  ADVERTISEMENT  
NEW Complement Coated C3 Control Cells!
Hemo bioscience has received FDA clearance for its complement coated control cells. Hemo bioscience C3 Control Cells can be used as a control to confirm the efficacy of the AHG reagent used during Direct and Indirect Anti-Globulin tests. For details regarding pricing, manufacturing schedule, and distribution channels email us or call 866-332-2835.

  Science & Health 
  • CDC: New HIV cases involving MSM rising
    The number of new HIV infections among young men who have sex with men rose by 22% from 2008 to 2010, and MSM now account for 66% of all new infections, according to a CDC report. The rate of new HIV cases among black women dropped 21%, but the total number of new HIV infections held steady at around 47,500. Reuters (12/19) LinkedInFacebookTwitterEmail this Story
  • Study yields promising results for skin infection drug
    The antibiotic oritavancin performed comparably with standard-of-care vancomycin in terms of efficacy, according to findings from a late-stage trial. The drug met the primary endpoint of the study, which was to halt the spread of the infection and to eliminate fever. The drug was tested for the treatment of acute bacterial skin and skin structure infections by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Reuters (12/20) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  • Mobile app gives patients quick access to hospital safety scores
    Leapfrog Group has introduced a Hospital Safety Score app, which includes patient-safety letter grades for more than 2,600 hospitals. The scores are based on measures such as infections, preventable errors and accidents. The app features GPS-supported search to connect users to nearby facilities, a map display, full grade details and a guide for hospital patients. Health Data Management (12/19) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • Report: Most states unprepared for health emergencies
    Only five states met eight of the 10 key measures for public emergency preparedness, according to an annual report released by the Trust for America's Health and the Robert Wood Johnson Foundation. Researchers found that 35 states, along with Washington, D.C., got a score of six or lower, with Kansas and Montana each receiving the lowest score of three. HealthDay News (12/19) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • European regulators approve iron overload drug
    The European Commission has granted Novartis approval for deferasirox to reduce iron overload in patients with nontransfusion-dependent thalassemia syndrome receiving chelation treatment. The approval was based on a study that showed use of deferasirox can lead to significant dose-dependent reduction in iron levels in the body. RTT News (12/21) LinkedInFacebookTwitterEmail this Story
  Association News 
  • Transfusion News video explores progress in treatment for thrombotic thrombocytopenic purpura
    A video posted on the Transfusion News website describes the use of immunomodulation therapy to help manage thrombotic thrombocytopenic purpura, or TTP, which is a rare but serious blood disorder that can cause catastrophic damage if not quickly diagnosed and treated. The video points out that earlier administration of rituximab, often with corticosteroids, may result in better patient outcomes. Progress in the treatment of TTP is discussed in an editorial and two reports appearing in the December issue of "Transfusion." Transfusion News is produced through a partnership between Ortho Clinical Diagnostics and AABB. The site features videos, articles, breaking news and commentary from transfusion and cellular therapy experts. Transfusion News may be accessed through the website for the journal "Transfusion," under "Special Features," or directly at www.TransfusionNews.com. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
Laboratory ManagerCreative Testing SolutionsUS - IL - Chicago
DIRECTOR, REGIONAL CENTER OPERATIONS IIUnited BloodUS - NV - Las Vegas
Quality SpecialistBlood Systems, Inc.US - NV - Las Vegas
Laboratory SupervisorCreative Testing SolutionsUS - IL - Chicago
LABORATORY MANAGERUnited Blood ServicesUS - NV - Las Vegas
DIRECTOR, COMMUNITY CENTER IUnited Blood ServicesUS - NV - Reno
QA SpecialistSan Diego Blood BankUS - CA
West Coast Account ManagerMacopharma USAUS - Nationwide
Reference TechnologistLifeStreamUS - CA - San Bernardino
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Click here to view more job listings.

  SmartQuote 
How we spend our days is, of course, how we spend our lives."
--Annie Dillard,
American author


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information